ACADIA Pharmaceuticals Inc. (ACAD) announced Thursday morning that the FDA has agreed that the data from the Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application for the treatment of Parkinson's disease psychosis. ACADIA will no longer conduct the Phase III -021 study that was planned as a confirmatory trial.
ACADIA Pharmaceuticals has gapped open sharply higher Thursday and is now up 3.47 at $11.44 on above average volume. The stock has jumped to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.